Prevalence of persistent symptoms at least 1 month after SARS-CoV-2 Omicron infection in adults

被引:5
|
作者
Gallant, Maxime [1 ]
Mercier, Kassandra [1 ]
Rioux-Perreault, Christine [1 ]
Lemaire-Paquette, Samuel [1 ]
Piche, Alain [1 ,2 ]
机构
[1] Clin Res Ctr Hosp Univ Sherbrooke CRCHUS, Sherbrooke, PQ, Canada
[2] Univ Sherbrooke, Dept Microbiol & Infectiol, Sherbrooke, PQ, Canada
来源
JOURNAL OF THE ASSOCIATION OF MEDICAL MICROBIOLOGY AND INFECTIOUS DISEASE CANADA (JAMMI) | 2022年 / 8卷 / 01期
关键词
BQC19; COVID-19; Omicron variant; post-COVID-19; condition; prevalence; vaccination;
D O I
10.3138/jammi-2022-0026
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Persistent post-COVID-19 symptoms pose an important health care burden. The Omicron variant has rapidly spread across the world and infected millions of people, largely exceeding previous variants. The potential for many of these people to develop persistent symptoms is a major public health concern. The aim of this study was to determine the prevalence and risk factors of post-COVID-19 symptoms associated with Omicron.Methods: We conducted a single-centre prospective observational study in Quebec, Canada, between December 2021 and April 2022. Participants were adults enrolled in the Biobanque Qu & eacute;b & eacute;coise de la COVID-19 (BQC19). Cases were considered Omicron cases as more than 85% were estimated to be attributable to Omicron variant during that period. Adults with polymerase chain reaction (PCR)-confirmed COVID-19 were recruited at least 4 weeks after the onset of infection.Results: Of 1,338 individuals contacted, 290 (21.7%) participants were recruited in BQC19 during that period. Median duration between the initial PCR test and follow-up was 44 days (IQR 31-56 d). A total of 137 (47.2%) participants reported symptoms at least 1-month post-infection. The majority (98.6%) had a history of mild COVID-19 illness. Most common persistent symptoms included fatigue (48.2%), shortness of breath (32.6%), and cough (24.1%). Number of symptoms during acute COVID-19 was identified as a risk factor for post-COVID-19 symptoms (OR 1.07 [95% CI 1.03% to 1.10%] p = 0.009).Conclusions: This is the first study reporting the prevalence of post-COVID-19 symptoms associated with Omicron in Canada. These findings will have important implications for provincial services planning. Historique : Les sympt & ocirc;mes post-COVID-19 persistants repr & eacute;sentent un fardeau important pour la sant & eacute;. Le variant Omicron s'est propag & eacute; rapidement dans le monde et a infect & eacute; des milliers de personnes, un nombre largement sup & eacute;rieur aux variants qui l'avaient pr & eacute;c & eacute;d & eacute;. Le risque que bon nombre d'entre elles acqui & egrave;rent des sympt & ocirc;mes persistants est un probl & egrave;me sanitaire majeur. La pr & eacute;sente & eacute;tude visait & agrave; d & eacute;terminer la pr & eacute;valence et les facteurs de risques de sympt & ocirc;mes post-COVID-19 li & eacute;s au variant Omicron.M & eacute;thodologie : Les chercheurs ont r & eacute;alis & eacute; une & eacute;tude observationnelle monocentrique & agrave; Qu & eacute;bec, au Canada, entre d & eacute;cembre 2021 et avril 2022. Les participants & eacute;taient des adultes inscrits & agrave; la Biobanque qu & eacute;b & eacute;coise de la COVID-19 (BQC19). Les cas & eacute;taient consid & eacute;r & eacute;s comme d & eacute;couler du variant Omicron parce que plus de 85% & eacute;taient estim & eacute;s y & ecirc;tre attribuables pendant cette p & eacute;riode. Les adultes atteints d'une COVID-19 confirm & eacute;e par un test d'amplification en cha & icirc;ne par polym & eacute;rase (PCR) ont & eacute;t & eacute; recrut & eacute;s au moins quatre semaines apr & egrave;s l'apparition de l'infection.R & eacute;sultats : Des 1 338 personnes contact & eacute;es, 290 (21,7%) ont & eacute;t & eacute; recrut & eacute;es dans la BQC19 pendant cette p & eacute;riode. La p & eacute;riode moyenne entre le test PCR initial et le suivi & eacute;tait de 44 jours (& Eacute;IQ: de 31 & agrave; 56 jours). Au total, 137 participants (47,2%) ont d & eacute;clar & eacute; des sympt & ocirc;mes au moins un mois apr & egrave;s l'infection. La majorit & eacute; avait & eacute;t & eacute; atteinte d'une COVID-19 l & eacute;g & egrave;re. Les sympt & ocirc;mes les plus persistants & eacute;taient la fatigue (48,2%), l'essoufflement (32,6%) et la toux (24,1%). Il a & eacute;t & eacute; & eacute;tabli que le nombre de sympt & ocirc;mes pendant la COVID-19 aigu & euml; (rapport de cotes: 1,07, IC & agrave; 95% 1,03% & agrave; 1,10%; p = 0,009) & eacute;tait un facteur de risque de sympt & ocirc;mes post-COVID-19.Conclusions : La pr & eacute;sente & eacute;tude est la premi & egrave;re & agrave; rendre compte de la pr & eacute;valence de sympt & ocirc;mes post-COVID-19 associ & eacute;s au variant Omicron au Canada. Ces observations auront des cons & eacute;quences importantes pour la planification des services provinciaux.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 50 条
  • [41] Prevalence and factors associated with SARS-CoV-2 infection in institutionalized older adults
    Buitrago-Gomez, Nathalia
    Zambrano-Urbano, Jose
    Munoz-Realpe, Juan
    Mauricio Ocampo-Chaparro, Jose
    Hernandez-Arango, Claudia
    Cristina Lesmes-Duque, Maria
    Elena Osorio-Amaya, Lyda
    Alfonso Reyes-Ortiz, Carlos
    DUAZARY, 2022, 19 (01) : 116 - 128
  • [42] Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?
    Goertz, Yvonne M. J.
    Van Herck, Maarten
    Delbressine, Jeannet M.
    Vaes, Anouk W.
    Meys, Roy
    Machado, Felipe V. C.
    Houben-Wilke, Sarah
    Burtin, Chris
    Posthuma, Rein
    Franssen, Frits M. E.
    van Loon, Nicole
    Hajian, Bita
    Spies, Yvonne
    Vijlbrief, Herman
    van't Hul, Alex J.
    Janssen, Daisy J. A.
    Spruit, Martijn A.
    ERJ OPEN RESEARCH, 2020, 6 (04) : 1 - 10
  • [43] Persistent somatic symptoms after a SARS-CoV-2 infection: Long COVID in the Dutch Lifelines Cohort study
    Ballering, Aranka Vivienne
    van den Bos, Nord
    Rosmalen, Judith
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2021, 145
  • [44] A Prospective Study of Patients with Persistent Symptoms After SARS-CoV-2 Infection Referred to Physical Medicine and Rehabilitation
    Romano, Joana
    Ribeiro, Pedro
    Alberto, Joana
    Almeida, Paula
    Dantas, Duarte
    ACTA MEDICA PORTUGUESA, 2023, 36 (10) : 639 - 646
  • [45] Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection
    Darley, David R.
    Dore, Gregory J.
    Cysique, Lucette
    Wilhelm, Kay A.
    Andresen, David
    Tonga, Katrina
    Stone, Emily
    Byrne, Anthony
    Plit, Marshall
    Masters, Jeffrey
    Tang, Helen
    Brew, Bruce
    Cunningham, Philip
    Kelleher, Anthony
    Matthews, Gail V.
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 214 (06) : 279 - 280
  • [46] Pathogenicity of SARS-CoV-2 Omicron
    Chu, Hin
    Yuen, Kwok-Yung
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
  • [47] Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
    Hromic-Jahjefendic, Altijana
    Lundstrom, Kenneth
    Adilovic, Muhamed
    Aljabali, Alaa A. A.
    Tambuwala, Murtaza M.
    Serrano-Aroca, Angel
    Uversky, Vladimir N.
    AUTOIMMUNITY REVIEWS, 2024, 23 (03)
  • [48] Evaluation of the presence of SARS-CoV-2 in vaginal and anal swabs of women with omicron variants of SARS-CoV-2 infection
    Liu, Ding
    Zhang, Yunfu
    Chen, Dongfeng
    Wang, Xianhua
    Huang, Fuling
    Long, Ling
    Zheng, Xiuhui
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [49] Risk of appendicitis after SARS-CoV-2 infection and SARS-CoV-2 vaccination
    Ljung, Rickard
    Pihlstrom, Nicklas
    Sundstrom, Anders
    BRITISH JOURNAL OF SURGERY, 2022, 109 (08) : 775 - 776
  • [50] Children with severe neurological symptoms associated with SARS-CoV-2 infection during Omicron pandemic in China
    Zhang, Tao
    Zhang, Qiao-Feng
    Yang, Hong-Mei
    Liu, Pin
    Sun, Peng
    Li, Yu-Mei
    Zhang, Zhen
    Huang, Yan-Zhi
    Yu, Xin-Yan
    Chao-Lu-Men, Qi-Qi-Ge
    Su, Qin
    Liu, Chun-Feng
    PEDIATRIC RESEARCH, 2024, 95 (04) : 1088 - 1094